23 Oct 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Roche has marketed the rights to Neupogen, Neulasta in 100 markets, including Asian, Eastern European, Middle Eastern, African, Latin American to Amgen.
The American Biopharmaceutical multinational has received the rights to drugs used to boost the immune systems of cancer patients on chemotherapy in these 100 markets.
Amgen has announced that the transfer of rights to Neupogen (filgrastim) and Neulasta (pegfilgrastim) would take effect on January 1, 2014.
The companies have not disclosed any financial terms of the acquisition of these drugs that have generated about $200 million in sales in all these countries last year.
"This agreement will enable Amgen to reach more patients around the world with two of our innovative medicines. The transaction will allow us to build experience and capacity in countries that will be important in accelerating future growth of Amgen's pipeline products," Mr Robert Bradway, chairman and CEO, Amgen has said.